363 related articles for article (PubMed ID: 18673221)
1. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
2. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
3. Small molecule protein-protein inhibitors for the p53-MDM2 interaction.
Dudkina AS; Lindsley CW
Curr Top Med Chem; 2007; 7(10):952-60. PubMed ID: 17508926
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of MDM2 and MDMX: a structural perspective.
Riedinger C; McDonnell JM
Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
[TBL] [Abstract][Full Text] [Related]
5. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
6. Targeting the MDM2-p53 interaction for cancer therapy.
Shangary S; Wang S
Clin Cancer Res; 2008 Sep; 14(17):5318-24. PubMed ID: 18765522
[TBL] [Abstract][Full Text] [Related]
7. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
8. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
9. Miniature protein inhibitors of the p53-hDM2 interaction.
Kritzer JA; Zutshi R; Cheah M; Ran FA; Webman R; Wongjirad TM; Schepartz A
Chembiochem; 2006 Jan; 7(1):29-31. PubMed ID: 16397877
[No Abstract] [Full Text] [Related]
10. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
[TBL] [Abstract][Full Text] [Related]
11. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
[TBL] [Abstract][Full Text] [Related]
12. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
Surmiak E; Twarda-Clapa A; Zak KM; Musielak B; Tomala MD; Kubica K; Grudnik P; Madej M; Jablonski M; Potempa J; Kalinowska-Tluscik J; Dömling A; Dubin G; Holak TA
ACS Chem Biol; 2016 Dec; 11(12):3310-3318. PubMed ID: 27709883
[TBL] [Abstract][Full Text] [Related]
13. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
14. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
[TBL] [Abstract][Full Text] [Related]
15. p53-Mdm2 inhibitors: patent review (2009 - 2010).
Kamal A; Mohammed AA; Shaik TB
Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
[TBL] [Abstract][Full Text] [Related]
16. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
20. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
